Monsanto's broad array of product offering in the Agricultural space has lead the market in recent years.
The company's Roundup Ready 2 Soybean treatment has been chosen to treat just under 50% of the US Acreage for 2018.
Monsanto's (expected) future integration with Bayer should boost guidance prospects.
However, with mounting expenses with product rollout and legal expenses with the Bayer merger, profits should be under pressure.
The company's sales growth is impressive, but with the continued Agricultural slump in the US, sales guidance should be lackluster.
I'm starting Monsanto with a $110.00 Price Target throughout 2018.
Stop positioned at $125.00 but remains flexible with the broader market.
The company's Roundup Ready 2 Soybean treatment has been chosen to treat just under 50% of the US Acreage for 2018.
Monsanto's (expected) future integration with Bayer should boost guidance prospects.
However, with mounting expenses with product rollout and legal expenses with the Bayer merger, profits should be under pressure.
The company's sales growth is impressive, but with the continued Agricultural slump in the US, sales guidance should be lackluster.
I'm starting Monsanto with a $110.00 Price Target throughout 2018.
Stop positioned at $125.00 but remains flexible with the broader market.